Literature DB >> 1251849

The bimodal mortality pattern of systemic lupus erythematosus.

M B Urowitz, A A Bookman, B E Koehler, D A Gordon, H A Smythe, M A Ogryzlo.   

Abstract

The changing pattern of mortality in systemic lupus erythematosus (SLE) led to an examination of the deaths in a long-term systematic analysis of 81 patients followed for five years at the University of Toronto Rheumatic Disease Unit. During the follow-up 11 patients died; six patients died within the first year after diagnosis (group I) and five patients died an average of 8.6 years (from 2.5 to 19.5 years) after diagnosis (group II). In those who died early, the SLE was active clinically and serologically, and nephritis was present in four. Their mean prednisone dose was 53.3 mg/day. In four patients a major septic episode contributed to their death. In those who died late in the course of the disease, only one patient had active lupus and none had active lupus nephritis. Their mean prednisone dose was 10.1 mg/day taken for a mean of 7.2 years. In none was sepsis a contributing factor to their death. All five of these patients had had a recent myocardial infarction at the time of death; in four, ti was the primary cause of death. Mortality in SLE follows a bimodal pattern. Patients who die early in the course of their disease, die with active lupus, receive large doses of steroids and have a remarkable incidence of infection. In those who die late in the course of the disease, death is associated with inactive lupus, long duration of steroid therapy and a striking incidence of myocardial infarction due to atherosclerotic heart disease.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1251849     DOI: 10.1016/0002-9343(76)90431-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  211 in total

1.  Inflammation-mediated rheumatic diseases and atherosclerosis.

Authors:  S Manzi; M C Wasko
Journal:  Ann Rheum Dis       Date:  2000-05       Impact factor: 19.103

2.  IFN-α Negatively Regulates the Expression of Endothelial Nitric Oxide Synthase and Nitric Oxide Production: Implications for Systemic Lupus Erythematosus.

Authors:  Joy Jones Buie; Ludivine L Renaud; Robin Muise-Helmericks; Jim C Oates
Journal:  J Immunol       Date:  2017-08-04       Impact factor: 5.422

3.  Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus.

Authors:  M B Urowitz; D Gladman; D Ibañez; S C Bae; J Sanchez-Guerrero; C Gordon; A Clarke; S Bernatsky; P R Fortin; J G Hanly; D J Wallace; D Isenberg; A Rahman; G S Alarcón; J T Merrill; E Ginzler; M Khamashta; O Nived; G Sturfelt; I N Bruce; K Steinsson; S Manzi; R Ramsey-Goldman; M A Dooley; A Zoma; K Kalunian; M Ramos; R F Van Vollenhoven; C Aranow; T Stoll; M Petri; P Maddison
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

4.  Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus.

Authors:  Aleksandar K Stanic; Charles M Stein; Adam C Morgan; Sergio Fazio; MacRae F Linton; Edward K Wakeland; Nancy J Olsen; Amy S Major
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-24       Impact factor: 11.205

Review 5.  Perioperative care for patients with rheumatic diseases.

Authors:  Bharath M Akkara Veetil; Tim Bongartz
Journal:  Nat Rev Rheumatol       Date:  2011-11-15       Impact factor: 20.543

6.  Perioperative management of patients with connective tissue disease.

Authors:  Susan M Goodman; Mark P Figgie; C Ronald Mackenzie
Journal:  HSS J       Date:  2010-08-17

7.  Autoimmune-mediated glucose intolerance in a mouse model of systemic lupus erythematosus.

Authors:  Curtis L Gabriel; Patricia B Smith; Yanice V Mendez-Fernandez; Ashley J Wilhelm; Audrey Musi Ye; Amy S Major
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-10-02       Impact factor: 4.310

8.  Telomere length in patients with systemic lupus erythematosus and its associations with carotid plaque.

Authors:  Carly Skamra; Juanita Romero-Diaz; Alexander Sandhu; QiQuan Huang; Jungwha Lee; William Pearce; David D McPherson; Kim Sutton-Tyrrell; Richard Pope; Rosalind Ramsey-Goldman
Journal:  Rheumatology (Oxford)       Date:  2013-02-04       Impact factor: 7.580

9.  Effect of high-dose methylprednisolone therapy on phagocyte function in systemic lupus erythematosus.

Authors:  S H Boghossian; D A Isenberg; G Wright; M L Snaith; A W Segal
Journal:  Ann Rheum Dis       Date:  1984-08       Impact factor: 19.103

10.  Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy.

Authors:  Howard A Austin; Gabor G Illei; Michelle J Braun; James E Balow
Journal:  J Am Soc Nephrol       Date:  2009-03-18       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.